Navigation Links
MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs
Date:1/12/2009

idates in Phase 3 clinical trials. Unit Dose Budesonide is being developed for the potential treatment of asthma in children, and MAP0004 is being developed for the potential treatment of migraine. MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and history.

Forward Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' late stage clinical programs. Actual results may differ materially from current expectations based on risks and uncertainties affecting MAP Pharmaceuticals' business, including, without limitation, risks and uncertainties relating to the failure to obtain clearance of the collaboration agreement with AstraZeneca under the Hart-Scott-Rodino Act, the enrollment, conduct, completion and reporting of clinical trials, as well as risks related to the failure to achieve favorable clinical outcomes or to have the company's product candidates approved for commercial use by the U.S. Food and Drug Administration. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals results and other risks and uncertainties are detailed in its Quarterly Report on Form 10-Q, filed with the SEC on November 13, 2008, and available at http://edgar.sec.gov.


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)...  Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... a privately held company based in ... a big data platform for centralized management and ... proprietary on-market Genomic Management Solution, Bina-GMS 1 , ... fast and scalable analyses to maximize the value ...
(Date:12/19/2014)... 2014 BioPlus Specialty Pharmacy ... pharmacies, has an expanded team of Regional Pharmaceutical ... for prescriber offices in their regions, with specific ... have a variety of Regional Pharmaceutical Care Liaisons ... in hepatitis C help prescribers understand all the ...
(Date:12/19/2014)... Reports from CDC show approximately 117 ... or more chronic health conditions - including cardiovascular disease, ... of these diseases, but may not eliminate the severe ... implanted nerve stimulation devices today offer relief, they require ... induce side effects. , To eliminate the need ...
(Date:12/19/2014)... 18, 2014 With only 2 weeks ... special on Sartorius Biohit products . The product specials ... Picus Electronic Pipette Trade-in Program, and free pipette tips. ... officers around the world. They are ideal for lab ... include:, ,     Full volume range of 0.1 ...
Breaking Biology Technology:Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2
... Germany and OXFORD, England, November 28, Evotec AG ... Polywka and Dr Klaus Maleck have been appointed ... Officer and,Chief Financial Officer., Jorn Aldag, President ... extremely pleased to announce the addition of Dr ...
... Nov. 27 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ... and,medical device company, is scheduled to participate in ... being held December 2 - 4 in Orlando, ... will give a 15-minute,formal presentation followed by a ...
... listing includes over 4,000 antibody products with documented ... ... Sigma-Aldrich(TM) (Nasdaq:,SIAL) is pleased to announce the new 2007-2008 ... (Photo: http://www.newscom.com/cgi-bin/prnh/20071127/AQTU011 ), The 320-page Sigma Antibodies ...
Cached Biology Technology:Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 2Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 3Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 4Sigma-Aldrich Announces Launch of a New Antibodies Catalog 2Sigma-Aldrich Announces Launch of a New Antibodies Catalog 3
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ... and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... DUBLIN , Dec. 16, 2014 Research ... announced the addition of the "Global Chemical ... http://photos.prnewswire.com/prnh/20130307/600769 ... is the increasing demand for medical sensors in ... patient data for quick and correct diagnosis during ...
(Date:12/11/2014)... -- That blood pressure plays a role in human health has ... term for high blood pressure – was first described as ... that,s used in measuring blood pressure was invented in 1896. ... hypertension, its triggers and its effects. In fact, recent findings ... best ways to treat it. For example, a ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... in the two chromosomes has given scientists a break ... College of Georgia researchers report. It,s also helped ... no sense of smell, said Dr. Lawrence C. Layman, ... and Genetics. The WRD11 gene interacts with a ...
... The National Institute of General Medical Sciences (NIGMS) ... of Yeshiva University a five-year, $30 million grant to ... important proteins. "Determining the structures of proteins is ... biological processes as well as in disease pathways," says ...
... An Australian study of identical twins shows that a rare ... mutation that occurs in the embryo, and not necessarily passed ... University of Melbourne and Austin Health and published in the ... Director of the Comprehensive Epilepsy Program at Austin Health and ...
Cached Biology News:Chromosomal break gives scientists a break in finding new puberty gene 2Chromosomal break gives scientists a break in finding new puberty gene 3Einstein receives $30 million to study protein form and function 2Einstein receives $30 million to study protein form and function 3Einstein receives $30 million to study protein form and function 4
... salt solution. It is routinely used as an ... blood at refrigerator temperatures for approximately 10 weeks.1 ... collected into a container of this product and ... in a refrigerator at 2-8 C for 2 ...
... OligoMix or individual RNA sequences from high throughput ... small RNAs from LC Sciences. These products provide ... millions) of DESIGNED sequences delivered in a microtube ... containing a single verified RNA sequence. This is ...
... Chromatograph/Mass Spectrometer, utilizing many of the ... offers high throughput and excellent productivity, ... ratio. Like the GCMS-QP2010 Plus, the ... for optimum separation, 20 temperature ramps, ...
... Assay Kit contains all reagents necessary to ... lineage, as determined by staining for mineralization. ... necessary reagents and a protocol for quantifying ... product is useful for studying the effects ...
Biology Products: